(TheNewswire)
Winnipeg, MB – TheNewswire -- February 7 , 2024 – Cytophage Technologies Ltd.(“Cytophage” or the “Company”) (TSXV:CYTO) (formerly CuspisCapital III Ltd. (“Cuspis”) (TSXV:CIII.P)) is pleased to announce that it has received its final bulletin from theTSX Venture Exchange Inc. (the “TSXV”), and is scheduled tocommence trading on February 9 th , 2024.
The decision to go - public represents asignificant milestone for Cytophage as it positions itself for growth,enhanced visibility, and increased potential commercial opportunities.The TSXV, known for its dynamic and innovative market, providesCytophage with a platform to access a broader investor base andfurther solidify its position as an integral contributor in the humanand animal health sector.
“We are thrilled to announce this important step in the evolution ofCytophage Technologies,” said Dr. Steven Theriault, CEO/Founder ofCytophage. “Becoming a publicly traded company on the TSX VentureExchange not only reflects the hard work and dedication of our teambut also demonstrates our commitment to advancing our phage productsthrough innovation and strategic growth initiatives.” Dr. Theriaultadded, “ 2024 is looking bright for the Company as weexpand our market reach for our agricultural products and venture intohuman health applications .” The Company’s listing on theTSXV is expected to increase liquidity for existing shareholders whileproviding a transparent and regulated platform for investors.
“On behalf of my Cuspis partners and shareholders, Iextend enthusiastic congratulations to Cytophage on successfullytransitioning to a public company (CYTO) through the completion ofthis transaction with Cuspis III.” said William Ollerhead, formerCEO of Cuspis and current director of Cytophage. “This is apivotal step in the growth and evolution of Cytophage andrepresents an opportunity to broaden awarenessand investor interest in the pioneering technology Cytophage is commercializing. Theconcerning rise of antimicrobial resistance, and the diminishingeffectiveness of antibiotics is increasingly the subject of newsstories and global healthcare discourse. We believe that theinnovative and novel initiatives being undertaken by Cytophage, fueledby transformative science, to counter these intensifying challenges, will gain increasingattention. I am genuinely optimistic about the positive impact Cytophage can make onaddressing these concerns.”
Cytophage is globally recognized for its innovative work with bacteriophages. TheCompany’s commitment to excellence, innovation, and sustainabilityhas garnered recognition within the industry, making it an attractiveinvestment opportunity for a wide range of investors.
Market Maker Agreement
Cytophage also announces that it has engaged Integral WealthSecurities Limited (“Integral”) to provide services as a marketmaker in compliance with the policies and guidelines of the TSXV andother applicable legislation. Under the agreement, Integral willreceive a fee of C$6,000 plus applicable taxes per month. The initialterm of the agreement is six (6) months from the date of execution.
For more information about Cytophage Technologies Ltd. and its listingon the TSXV, please visit https://cytophage.com/news/
For media inquiries, kindly reach out to:
Heather Medwick
President
heather@cytophage.com
431 388 8873
About Cytophage
Cytophage is a pioneering biotechnology company dedicated tobacteriophage research, product development and commercialization.Committed to addressing the global challenge of antibiotic resistance,Cytophage advances innovative therapies that harness the power ofbacteriophages to combat bacterial infections affecting human health,animal health, and food security.
Cautionary Statement onForward-Looking Information
This news release contains“forward-looking information” and “forward-looking statements”(collectively, “forward-looking statements”) within the meaning ofthe applicable Canadian securities legislation. All statements, otherthan statements of historical fact, are forward-looking statements andare based on expectations, estimates and projections as at the date ofthis news release. Any statement that involves discussions withrespect to predictions, expectations, beliefs, plans, projections,objectives, assumptions, future events or performance (often but notalways using phrases such as “expects”, or “does not expect”,“is expected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements.
Forward-looking statements involveknown and unknown risks, uncertainties and other factors which maycause the actual results, performance or achievements of Cytophage tobe materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are describedunder the caption “Risk Factors” in Cytophage’s Filing Statementdated January 30, 2024, which is available for view on SEDAR+at www.sedarplus.ca. These risks include but are not limited to, the risks associatedwith the bacteriophage industry, such as operational risks indevelopment or capital expenditures, the uncertainty of extensiveregulatory approval requirements, government regulations, protectionof intellectual property, product liability and rapid technologicaladvancements. Forward-looking statements contained herein are made asof the date of this press release, and Cytophage disclaims, other thanas required by law, any obligation to update any forward-lookingstatements whether as a result of new information, results, futureevents, circumstances, or if management’s estimates or opinionsshould change, or otherwise. There can be no assurance thatforward-looking statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, the reader is cautionednot to place undue reliance on forward-looking statements.
Neither the TSXV nor its Regulation Services Provider (as that term isdefined in the policies of the TSXV) accepts responsibility for theadequacy or accuracy of this news release.
Copyright (c) 2024 TheNewswire - All rights reserved.